Attention Deficit Hyperactivity Disorder (ADHD): Market Intelligence Review and Insights 2018 - ResearchAndMarkets.com

DUBLIN--()--The "Attention Deficit Hyperactivity Disorder (ADHD): Market Intelligence Review and Insights" report has been added to ResearchAndMarkets.com's offering.

This report delivers an in-depth understanding of the disease, and cover in detail the major research events, competitor events, physicians and patients findings updates in a month and their potential implications on the market and the pharmaceutical firms researching or marketing their drugs in the disease area.

Disease Indication Overview: This section of report gives the overview of Attention Deficit Hyperactivity Disorder (ADHD) disease indication in detail. The section highlights the basic definition, causes and symptoms of disease and further details the types of ADHD disease. Further details on the profile of ADHD patients, Symptoms experienced by the patients, and disease progression in patients are outlined in the report. The report further highlights the multiple methods through which the patient can be diagnosed for ADHD disease.

Market Intelligence Information Overview and Potential Implications

  • The report covers in detail the market updates in the form of major research events in the disease area including the Congresses' events updates, Clinical Trial results and updates, Latest Research findings from scientific institutions and observational/interventional studies, Regulatory bodies updates, Patients and Physicians findings from multiple sources.
  • The report also covers in detail the latest updates related to drugs and other activities from Companies, operating and researching in the disease indication. The Company activities included in the report cover Drug approval events, Clinical updates for drugs including new Safety and Regulatory warnings from Regulatory bodies, promotional activities, Investor events, Mergers and Acquisitions details for the companies etc.
  • The report further details the potential implications, of every event covered, on the Market and the Pharmaceutical firms researching or marketing their drugs in the disease area, both in short-term and long-term. This in turn would enable firms to keep a close watch on the competitor drugs in the market and prepare well in advance for the implications of competitor activities to gain or retain majority share in the market.

Companies Mentioned

  • Chugai Pharmaceutical
  • Roche
  • AC Immune
  • Eli Lilly
  • PDL BioPharma
  • NovaQuest Capital Management
  • Bayer
  • TauRx Pharmaceuticals
  • Forest Laboratories
  • Daiichi Sankyo
  • Lundbeck
  • Allergan
  • Merz
  • Neurobiological Technologies
  • Adamas Pharmaceuticals
  • Wyeth
  • Eisai
  • Pfizer
  • Daewoong Pharmaceutical
  • Nitto Denko
  • Teikoku Seiyaku
  • Ono Pharmaceutical
  • Abbott Laboratories
  • BASF
  • Novartis
  • Esteve
  • LTS Gruppe
  • Johnson & Johnson
  • Shire
  • Takeda
  • Astex Pharmaceuticals
  • AstraZeneca
  • ACADIA Pharmaceuticals
  • Ipsen
  • Shionogi

For more information about this report visit https://www.researchandmarkets.com/research/6tmbpv/attention_deficit?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Mental Disorders Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Mental Disorders Drugs